# A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis

> **NCT03949530** · PHASE1 · TERMINATED · sponsor: **Indalo Therapeutics, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Healthy Volunteers
- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** IDL-2965 Oral Capsule
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03949530
- **Lead sponsor:** Indalo Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-16
- **Primary completion:** 2020-03-29
- **Final completion:** 2020-03-29
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Due to development challenges associated with the SARS-CoV-2 pandemic and emerging nonclinical data
- **Last updated:** 2020-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03949530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03949530, "A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03949530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*